Clinicogenomics

Guide Early Discovery for Clinical Development

Enrich real-world oncology patient data with comprehensive genomic profiling information to discover hidden patterns and inform early-stage drug discovery research.

Group 48
Use Cases

Future-Plan for Clinical Research and Development

Clinicogenomics is an optional add-on designed to enrich our robust oncology patient data with genomic markers to help generate insights about new research and development opportunities.

Genomic Data Includes:

Group 213

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Group 203
Additional Support

Get the Most of Your Clinicogenomics Data with Real-World Insights and Support

Real-World Support gives you access to industry veterans who can help you structure study designs, provide guidance on protocol and analysis,
make recommendations for regulatory submission packets, review research and manuscripts, and more to ensure your research achieves the highest quality standards.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Extending COTA’s global reach with RWD in oncology research

Cancer is a disease that respects no borders: it affects everyone around the world, no matter where they live.  The...

3 key takeaways from ASCO 2025: Staying nimble in a changing environment

3 key takeaways from ASCO 2025: Staying nimble in a changing environment The annual meeting of the American Society of...

Reflections on ISPOR: Shifting data dynamics open new opportunities for RWD and RWE

Each year, ISPOR brings together members of the health economics and outcomes research (HEOR) community for a celebration of the...

Find Your Next Breakthrough

Discover the power of real world cancer data to help you understand patient journeys across the oncology spectrum and inform research directions.
Group 11